COVID-19 is the infectious disease caused by the strain of SARS-CoV-2 Coronavirus.
On 11 March 2020, the WHO declared the disease a pandemic, due to the high number of individuals infected and its rapid spread around the world.
CerTest has been working urgently and determinedly since the start of the spread of the virus to collaborate in the global response to this serious disease, which affects the whole society. It develops reliable and accurate diagnostic assays, essential for healthcare systems.
CerTest bioSCIENCE: Raw materials
Highly sensitive and specific high quality recombinant proteins and monoclonal antibodies, for the development of diagnostic assays for SARS-CoV-2 and other coronaviruses.
Suitable for Lateral Flow, CLIA and ELISA assay!
bioSCIENCE products linked with SARS-CoV-2
Do you have questions about CerTest bioSCIENCE?
Rapid Test for antigen detection
One step immunochromatographic assays for the qualitative detection of SARS-CoV-2 antigens using nasopharyngeal swabs taken from patients showing symptoms of COVID-19 infection.
Rapid Test products linked with SARS-CoV-2 antigen detection
Do you have questions about rapid antigen tests?
VIASURE Real Time PCR
Real Time PCR tests designed for the identification of SARS-CoV-2 in respiratory samples from patients with signs and symptoms of COVID-19 infection.
VIASURE products linked with SARS-CoV-2
Do you have any questions about VIASURE Real Time PCR?
CerTest offers a complete panel of reliable and highly sensitive diagnostic assays for the diagnosis of SARS-CoV-2 and other respiratory diseases.
We have more than 15 years of experience and dedication to the development of diagnostic assays for infectious diseases behind us.
The clinical forms of this disease range from mild to very severe symptoms: pneumonia, a temperature and respiratory symptoms are the most common.
Other symptoms of the viral infection include a sore throat, aches and pains, or difficulty breathing. In some cases there may be nasal secretion, nausea and diarrhea.
The recently discovered outbreak of coronavirus starts mainly with nasal secretions or drops of saliva, once an infected individual sneezes or coughs. The estimated incubation time is 2 weeks. Due to the high rate of SARS-CoV-2 infection, the detection of asymptomatic positive patients is ,probably one of the key factors for controlling the outbreak.
The coronaviruses (CoV) are RNA, enveloped viruses, with a large genome (29.9 kb), of which the β-CoV and α-CoV are able to infect mammals.
The viruses belonging to the Coronaviridae family contain a higher abundance of the membrane protein (M) abundant among other proteins, that is, the peak glycoprotein (S), the nucleocapsid protein (N) and an envelope protein (E). The spike glycoprotein (S) is one of the targets of the T-cell response in the immune system. The S protein also facilitates the fusion of the viral envelope to the receptor ACE2 and the entrance of the virus in the target cell. The ACE2 receptors are present in the cells of the arteries, veins, smooth muscles, small intestine, lung alveoli, hair follicles, cardiac myofibroblasts, skin, brain and kidney. Consequently, the SARS-CoV-2 can potentially infect these tissues.
In December 2019, certain individuals working or living in the vicinity of the Huanan seafood market in Wuhan, in the province of Hubei, China, developed pneumonia of unknown cause.
Massive sequencing analysis of the respiratory samples revealed a new coronavirus, initially known as 2019 new coronavirus (2019-nCoV) and subsequently renamed as SARS-CoV-2.
On 11 March 2020, the WHO declared the disease a pandemic, due to the high number of individuals infected and the rapid spread of the disease around the world.